Navigation Links
Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Date:7/30/2009

SAN DIEGO, July 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
2. AHIMA Enters Multinational Arena to Support HIM Worldwide Advancement
3. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Arena Pharmaceuticals Announces Public Offering of Common Stock
5. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
6. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
7. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
8. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
9. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
10. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Universities of Manchester and Auckland suggest that both major forms ... , The findings, published today in the FASEB Journal ... diabetes and type-2 diabetes are both caused by the formation ... , The results, based on 20 years, work in New ... slowed down and potentially reversed by medicines that stop amylin ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies ... for its annual fall conference, WEDI-Con 2014: The ... will take place at the HYATT Regency in ... diverse cross-section of payers, providers, government regulators, industry ...
(Date:8/20/2014)... August 20, 2014 If old age is ... cure for it. With extensive research on HGH and stem ... claims to have perfected the art of rubbing off decades ... new younger look with their revolutionary anti-aging hormone therapy and ... 21st century fountain of youth, the MD of MetroMD, Dr ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
Breaking Medicine News(10 mins):Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... 18 Codexis, Inc. today announced that Joseph Sarret, ... Corporate Development from his previous position as Vice President, ... Shaw, Ph.D., President and CEO. Dr. Sarret was ... joined Codexis in 2005 as Corporate Counsel and Director, ...
... Inc. (Nasdaq: MDVN ) today announced ... U.S. Food and Drug Administration (FDA) to begin ... novel androgen receptor antagonist, in patients with metastatic ... chemotherapy. The placebo-controlled, double-blind, multinational trial will ...
... smaller and more contained, study finds , , WEDNESDAY, March 18 ... reduce the risk of death by as much as half, ... information on 1,044 women who were seen at a medical ... had developed a second breast cancer -- 455 with cancer ...
... PHR Taps into Latino Market Underserved by ... Information Systems, Inc. (OTC Bulletin Board: FVRL), ... Inc. (collectively, "MMR") provides consumer-controlled Personal Health ... safe deposit box storage solutions ( www.myesafedepositbox.com ...
... 18 Kensey Nash Corporation (Nasdaq: KNSY ) ... stock repurchase. The new program allows the Company to ... and outstanding shares of Common Stock and has no scheduled ... its available cash. "Given our strong cash position and the ...
... they learned from elders who have been through economic ... simply being thankful can calm economic anxiety; other key ... optimism; what to avoid?: elders say don,t listen to ... released in conjunction with national conference Aging in America ...
Cached Medicine News:Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:New Survey: Top Lesson from Seniors About Economic Worries? Gratitude Trumps Fear 2
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: